Interventional Treatment Strategies in Intrahepatic Cholangiocarcinoma and Perspectives for Combined Hepatocellular-Cholangiocarcinoma

Simple Summary Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a rare form of liver cancer with features of both hepatocellular and biliary tract cancer. Locoregional tumor therapies are an integral part of the treatment strategies of hepatocellular carcinomas (HCC) and intrahepatic cholangiocarcinoma (iCCA). Due to the rarity of cHCC-CCA, no interventional therapies have been established. This review provides an overview of current radiologic interventions for CCA (excluding options for eCCA), to review and appraise the existing literature on the topic, and to provide an outlook on whether such interventions may have a role as treatment for cHCC-CCA in the future. Abstract cHCC-CCA is an uncommon type of liver cancer that exhibits clinical and pathological characteristics of both hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA), which are the two main forms of primary liver cancer. The similarity to HCC and CCA makes therapeutical strategies challenging. The poor prognosis of CCA in general, as well as for cHCC-CCA, is mainly attributable to the fact that diagnosis is often at an advanced stage of disease. During the last decade, locoregional therapies usually performed by interventional radiologists and its established role in HCC treatment have gained an increasing role in CCA treatment as well. These comprise a wide range of options from tumor ablation procedures such as radiofrequency ablation (RFA), microwave ablation (MWA), computed tomography high-dose rate brachytherapy (CT-HDRBT), and cryoablation to transarterial chemoembolization (TACE), including the option of intra-arterial administration of radioactive spheres (transarterial radioembolization—TARE), and much attention has focused on the potential of individual concepts in recent years. The purpose of this review is to provide an overview of current radiologic interventions for CCA (excluding options for eCCA), to review and appraise the existing literature on the topic, and to provide an outlook on whether such interventions may have a role as treatment for cHCC-CCA in the future.

[1]  J. Theysohn,et al.  Real-Life Experience in the Treatment of Intrahepatic Cholangiocarcinoma by 90Y Radioembolization: A Multicenter Retrospective Study , 2022, The Journal of Nuclear Medicine.

[2]  Guo-hui Xu,et al.  Efficacy and Safety of Drug-Eluting Beads Transarterial Chemoembolization Combining Immune Checkpoint Inhibitors in Unresectable Intrahepatic Cholangiocarcinoma: A Propensity Score Matching Analysis , 2022, Frontiers in Immunology.

[3]  M. Rebelatto,et al.  Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study. , 2022, The lancet. Gastroenterology & hepatology.

[4]  R. Salem,et al.  TARE in Hepatocellular Carcinoma: From the Right to the Left of BCLC , 2022, CardioVascular and Interventional Radiology.

[5]  Akshya Gupta,et al.  Transarterial yrittrium-90 radioembolization for unresectable intrahepatic cholangiocarcinoma: a systematic review and meta-analysis. , 2022, Journal of vascular and interventional radiology : JVIR.

[6]  M. Girotra,et al.  Radiofrequency ablation in the management of primary hepatic and biliary tumors , 2022, World journal of gastrointestinal oncology.

[7]  M. Schmelzle,et al.  Treatment of Intrahepatic Cholangiocarcinoma—A Multidisciplinary Approach , 2022, Cancers.

[8]  A. Ni Eochagain Cryoshock following cryoablation for hepatocellular carcinoma , 2022, Journal of Clinical Anesthesia.

[9]  P. Kim,et al.  Thermal ablation in the treatment of intrahepatic cholangiocarcinoma: a systematic review and meta-analysis , 2021, European Radiology.

[10]  R. Salem,et al.  Review of Use of Y90 as a Bridge to Liver Resection and Transplantation in Hepatocellular Carcinoma , 2021, Journal of Gastrointestinal Surgery.

[11]  R. Golfieri,et al.  Locoregional Treatments in Cholangiocarcinoma and Combined Hepatocellular Cholangiocarcinoma , 2021, Cancers.

[12]  G. Brandi,et al.  Neoadjuvant therapy for cholangiocarcinoma: A comprehensive literature review. , 2021, Cancer treatment and research communications.

[13]  K. Chigurupalli,et al.  Role of intraluminal brachytherapy as a palliative treatment modality in unresectable cholangiocarcinomas , 2021, Journal of cancer research and therapeutics.

[14]  A. Zhu,et al.  Biliary tract cancer , 2021, The Lancet.

[15]  G. Brandi,et al.  Immunotherapy in Biliary Tract Cancer: Worthy of a Second Look , 2020, Cancer control : journal of the Moffitt Cancer Center.

[16]  G. Gores,et al.  Cholangiocarcinoma 2020: the next horizon in mechanisms and management , 2020, Nature Reviews Gastroenterology & Hepatology.

[17]  R. Shroff,et al.  New Treatment Options for Advanced Biliary Tract Cancer , 2020, Current Treatment Options in Oncology.

[18]  B. Hamm,et al.  Trans-arterial chemoembolization with degradable starch microspheres (DSM-TACE) versus selective internal radiation therapy (SIRT) in multifocal hepatocellular carcinoma , 2020, Acta radiologica.

[19]  Y. Rolland,et al.  Personalised Dosimetry in Radioembolisation for HCC: Impact on Clinical Outcome and on Trial Design , 2020, Cancers.

[20]  Kevin B. Taylor,et al.  Yttrium-90 Radioembolization in Intrahepatic Cholangiocarcinoma: A Multicenter Retrospective Analysis. , 2020, Journal of vascular and interventional radiology : JVIR.

[21]  J. Tabibian,et al.  Ablative therapies for hepatic and biliary tumors: endohepatology coming of age. , 2020, Translational gastroenterology and hepatology.

[22]  J. Ferlay,et al.  Global trends in intrahepatic and extrahepatic cholangiocarcinoma incidence from 1993 to 2012 , 2020, Cancer.

[23]  D. Mirza,et al.  The role of down staging treatment in the management of locally advanced intrahepatic cholangiocarcinoma: Review of literature and pooled analysis , 2020, Annals of hepato-biliary-pancreatic surgery.

[24]  G. Gores,et al.  Systemic therapies for intrahepatic cholangiocarcinoma. , 2020, Journal of hepatology.

[25]  D. Schnapauff,et al.  Feasibility and Safety of CT-Guided High-Dose-Rate Brachytherapy Combined with Transarterial Chemoembolization Using Irinotecan-Loaded Microspheres for the Treatment of Large, Unresectable Colorectal Liver Metastases. , 2020, Journal of vascular and interventional radiology : JVIR.

[26]  J. Sweeney,et al.  Ablation of Intrahepatic Cholangiocarcinoma , 2019, Seminars in Interventional Radiology.

[27]  A. Forner,et al.  Clinical presentation, diagnosis and staging of cholangiocarcinoma , 2019, Liver international : official journal of the International Association for the Study of the Liver.

[28]  W. Xu,et al.  Ultrasound-guided percutaneous microwave ablation versus surgical resection for recurrent intrahepatic cholangiocarcinoma: intermediate-term results , 2019, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[29]  B. Hamm,et al.  Cholangiocarcinoma: CT-guided High-Dose Rate Brachytherapy (CT-HDRBT) for Limited (<4 cm) and Large (>4 cm) Tumors , 2018, AntiCancer Research.

[30]  A. Gangi,et al.  Intrahepatic Cholangiocarcinoma Treated with Transarterial Yttrium-90 Glass Microsphere Radioembolization: Results of a Single Institution Retrospective Study. , 2018, Journal of vascular and interventional radiology : JVIR.

[31]  Kathryn J Fowler,et al.  cHCC‐CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation , 2018, Hepatology.

[32]  P. Liang,et al.  Clinical and survival outcomes of percutaneous microwave ablation for intrahepatic cholangiocarcinoma , 2018, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[33]  S. Silverman,et al.  Percutaneous Image-Guided Cryoablation of Hepatic Tumors: Single-Center Experience With Intermediate to Long-Term Outcomes. , 2017, AJR. American journal of roentgenology.

[34]  A. Zhu,et al.  New Horizons for Precision Medicine in Biliary Tract Cancers. , 2017, Cancer discovery.

[35]  H. El‐Serag,et al.  Epidemiology of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma , 2017, Cancer control : journal of the Moffitt Cancer Center.

[36]  K. Brown,et al.  Liver-Directed Therapies for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma , 2017, Cancer control : journal of the Moffitt Cancer Center.

[37]  T. Jiang,et al.  Ablation of hepatic malignant tumors with irreversible electroporation: A systematic review and meta-analysis of outcomes , 2016, Oncotarget.

[38]  J. Crezee,et al.  Time-Dependent Impact of Irreversible Electroporation on Pancreas, Liver, Blood Vessels and Nerves: A Systematic Review of Experimental Studies , 2016, PloS one.

[39]  K. Boberg,et al.  Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA) , 2016, Nature Reviews Gastroenterology &Hepatology.

[40]  R. Salem,et al.  Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma , 2016, Advances in Therapy.

[41]  Andrew X. Zhu,et al.  Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise , 2016, The oncologist.

[42]  P. Kim,et al.  Radiofrequency ablation in the treatment of unresectable intrahepatic cholangiocarcinoma: systematic review and meta-analysis. , 2015, Journal of vascular and interventional radiology : JVIR.

[43]  D. Pinto dos Santos,et al.  Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma , 2015, BMC Cancer.

[44]  Jian-hua Wang,et al.  Percutaneous microwave ablation combined with simultaneous transarterial chemoembolization for the treatment of advanced intrahepatic cholangiocarcinoma , 2015, OncoTargets and therapy.

[45]  B. Hamm,et al.  CT-guided high-dose-rate brachytherapy of unresectable hepatocellular carcinoma , 2015, Strahlentherapie und Onkologie.

[46]  T. Vogl,et al.  Image-guided tumor ablation: standardization of terminology and reporting criteria--a 10-year update. , 2014, Journal of vascular and interventional radiology : JVIR.

[47]  Y. Fong,et al.  Outcomes in biliary malignancy , 2014, Journal of surgical oncology.

[48]  T. Pawlik,et al.  Treatment and Prognosis for Patients With Intrahepatic Cholangiocarcinoma: Systematic Review and Meta-analysis. , 2014, JAMA surgery.

[49]  R. Golfieri,et al.  Trends in Utilization of Transarterial Treatments for Hepatocellular Carcinoma: Results of a Survey by the Italian Society of Interventional Radiology , 2014, CardioVascular and Interventional Radiology.

[50]  M. Kuang,et al.  Thermal Ablation Versus Repeated Hepatic Resection for Recurrent Intrahepatic Cholangiocarcinoma , 2013, Annals of Surgical Oncology.

[51]  Anita Andreano,et al.  A Comparison of Direct Heating During Radiofrequency and Microwave Ablation in Ex Vivo Liver , 2013, CardioVascular and Interventional Radiology.

[52]  P. Wust,et al.  Preliminary experience with CT-guided high-dose rate brachytherapy as an alternative treatment for hepatic recurrence of cholangiocarcinoma. , 2012, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[53]  J. Trojan,et al.  Transarterial chemoembolization in the treatment of patients with unresectable cholangiocarcinoma: Results and prognostic factors governing treatment success , 2012, International journal of cancer.

[54]  B. Xing,et al.  Radiofrequency ablation in the management of unresectable intrahepatic cholangiocarcinoma. , 2012, Journal of vascular and interventional radiology : JVIR.

[55]  H. Blum,et al.  Treatment of unresectable cholangiocarcinoma: conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy , 2012, European journal of gastroenterology & hepatology.

[56]  H-X Xu,et al.  Percutaneous ultrasound-guided thermal ablation for intrahepatic cholangiocarcinoma. , 2011, The British journal of radiology.

[57]  M. Reiser,et al.  Transarterial Hepatic Yttrium-90 Radioembolization in Patients with Unresectable Intrahepatic Cholangiocarcinoma: Factors Associated with Prolonged Survival , 2012, CardioVascular and Interventional Radiology.

[58]  B. Hamm,et al.  Computed Tomography-Guided Interstitial HDR Brachytherapy (CT-HDRBT) of the Liver in Patients with Irresectable Intrahepatic Cholangiocarcinoma , 2011, CardioVascular and Interventional Radiology.

[59]  I-S Lee,et al.  Transarterial chemoembolization versus supportive therapy in the palliative treatment of unresectable intrahepatic cholangiocarcinoma. , 2011, Clinical radiology.

[60]  D. Fraker,et al.  Chemoembolization of intrahepatic cholangiocarcinoma with cisplatinum, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol , 2011, Cancer.

[61]  H. Ohge,et al.  Prognostic Factors After Surgical Resection for Intrahepatic, Hilar, and Distal Cholangiocarcinoma , 2011, Annals of Surgical Oncology.

[62]  C. Georgiades,et al.  Radiofrequency ablation: mechanism of action and devices. , 2010, Journal of vascular and interventional radiology : JVIR.

[63]  P. Huppert,et al.  Transarterial chemoembolization of liver metastases in patients with uveal melanoma. , 2010, European Journal of Radiology.

[64]  R. Lencioni,et al.  Quality Improvement Guidelines for Radiofrequency Ablation of Liver Tumours , 2009, CardioVascular and Interventional Radiology.

[65]  Giovanni Simonetti,et al.  Percutaneous Cryoablation of Small Hepatocellular Carcinoma with US Guidance and CT Monitoring: Initial Experience , 2008, CardioVascular and Interventional Radiology.

[66]  S. Taylor-Robinson,et al.  Cholangiocarcinoma , 2005, The Lancet.

[67]  M. Miyazaki,et al.  Results of surgical treatment for intrahepatic cholangiocarcinoma and clinicopathological factors influencing survival , 2002, The British journal of surgery.

[68]  Ramon Planas,et al.  Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial , 2002, The Lancet.

[69]  T. Helling Realistic expectations for cryoablation of liver tumors. , 2000, Journal of hepato-biliary-pancreatic surgery.

[70]  J. Kuhlman,et al.  CT-monitored percutaneous cryoablation in a pig liver model: pilot study. , 1999, Radiology.

[71]  David L. Morris,et al.  World Survey on the Complications of Hepatic and Prostate Cryotherapy , 1999, World Journal of Surgery.

[72]  L Solbiati,et al.  Ablation of liver tumors using percutaneous RF therapy. , 1998, AJR. American journal of roentgenology.

[73]  J Bastacky,et al.  The process of freezing and the mechanism of damage during hepatic cryosurgery. , 1988, Cryobiology.

[74]  A. Segal,et al.  A Computational Model of the Electromagnetic Heating of Biological Tissue with Application to Hyperthermic Cancer Therapy , 1983, IEEE Transactions on Biomedical Engineering.

[75]  J. O. Forsberg Transient blood flow reduction induced by intra-arterial injection of degradable starch microspheres. Experiments on rats. , 1978, Acta chirurgica Scandinavica.

[76]  M. Dumont,et al.  European Association for the Study of the Liver , 1971 .